Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > ARCHIVE
ARCHIVE
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
- Novartis, Ono to Promote Rivastigmine Stressing Its Beneficial Effects on ADL
June 27, 2011
- All Clinical Studies Need to Be Conducted According to Global Standards: Expert Committee
June 27, 2011
- Lenvatinib Shows ORR of 59% in Global PII: Eisai
June 27, 2011
- Merck to License Biosimilar of Enbrel from Hanwha of South Korea
June 27, 2011
- Daiichi Sankyo Confident about Independently Expanding Share for Memary
June 27, 2011
- Korosho to Enhance Generics' Reliability: Minister Hosokawa
June 27, 2011
- PIII Study Confirms Safety, Efficacy of Rotigotine Patch: Otsuka
June 27, 2011
- Mr Yoshida Points Out Need to Review NHI Pricing Rules for Generics
June 27, 2011
- Janssen, Takeda to Expand Share of Reminyl through Comarketing
June 27, 2011
- JACDS Draws Up GL for Power Saving This Summer
June 27, 2011
- TS-1 Non-Inferior to Gemcitabine in Pancreatic Cancer: Taiho
June 27, 2011
- Study Group to Discuss System for Relieving Victims of Health Damage Due to Anticancer Drugs
June 27, 2011
- Combined Sales of 24 Drug Makers Show Zero Growth
June 27, 2011
- FDA Approves Ciclesonide in Alternative HFA for Rhinitis: DSP
June 27, 2011
- Sanofi: Lyxumia Plus Insulin Shows Promise in PIII Study
June 27, 2011
- Korosho Council Approves Draft Report on Measures against Rheumatism, Allergy
June 27, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…